UNIVERSITY OF SOUTH FLORIDA

Dupixent significantly reduced itch and hive activity in uncontrolled chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. The Phase 3 LIBERTY-CUPID Study C results support a U.S. regulatory resubmission by year-end, potentially making Dupixent the first new targeted treatment for CSU in over 10 years.

Regeneron and Sanofi present positive Phase 3 LIBERTY-CUPID Study C data on Dupixent in biologic-naïve CSU patients, showing significant itch and urticaria activity reduction and higher disease control rates compared to placebo, presented at ACAAI 2024.

Dupixent significantly reduced itch and hive activity in chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. Positive phase 3 data to be presented at ACAAI 2024, supporting potential US regulatory resubmission by year-end, aiming for Dupixent to become the first new targeted treatment for CSU in over 10 years.

Nipocalimab, a monoclonal antibody, showed promising results in the phase 3 VIVACITY-MG3 trial for generalized myasthenia gravis (gMG), meeting primary and secondary endpoints with a rapid and maintained reduction in MG-ADL scores. The treatment was well-tolerated with no new safety signals. Presented at the 2024 AANEM meeting, the study highlights nipocalimab's potential as a steady, IV-administered option for gMG, contrasting with currently available cyclical treatments.

FDA approves Vyalev, a 24-hour subcutaneous levodopa infusion for advanced Parkinson's disease, showing superior motor fluctuation control compared to oral carbidopa/levodopa. AbbVie's Vyalev aims to provide continuous symptom management without surgery, with Medicare coverage expected in 2025.

The FDA approved VYALEV, a 24-hour continuous infusion of levodopa-based medication for advanced Parkinson’s disease, offering a non-surgical alternative to oral medications. VYALEV, composed of foscarbidopa and foslevodopa, demonstrated superior improvement in motor fluctuations in pivotal and open-label studies, though it also showed common side effects like infusion site events, hallucinations, and dyskinesia.

FDA approves VYALEV, first subcutaneous 24-hour levodopa infusion for advanced Parkinson's, addressing motor fluctuations. VYALEV showed superior 'on' time and reduced 'off' time in Phase 3 study, with mild to moderate adverse reactions.

FDA approves AbbVie's Vyalev, a 24-hour infusion therapy using prodrug versions of carbidopa and levodopa for advanced Parkinson’s patients, offering continuous symptom control without surgery.

FDA approves VYALEV, the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for motor fluctuations in advanced Parkinson's disease.

FDA approves foscarbidopa/foslevodopa (Vyalev; AbbVie) for motor fluctuations in advanced Parkinson disease, the first subcutaneous 24-hour levodopa-based infusion therapy, supported by phase 3 trial results showing safety, efficacy, and improved motor symptoms.